infection, anaphylactic reaction, azospermia, liver toxicity, and severe nausea in 1 patient each. Overall, 16 malignancies were observed in 14 (7%) patients after a median follow-up of 25 (IQR: 15–26) years. The malignancies were bladder carcinoma (n=4), lung adenocarcinoma (n=3), prostate adenocarcinoma (n=2), carcinoma of unknown primary origin, pancreas adenocarcinoma, t-MDS-AML, lymphoma, colon adenocarcinoma, squamous cell carcinoma and thyroid papillary carcinoma. Among the 113 patients, we were able to question regarding infertility, 67 patients (59%) had children, 22 (19.5%) did not wish to have a child and 24 (21.5%) tried to have a child, but was not able to.

Conclusions: Short term serious adverse events occurred in 8% of the patients during CYC treatment. During long term follow-up malignancies occurred in 7% and infertility in 21.5% of the patients. These results underline the need for safer and effective alternatives to CYC for serious organ involvement in BS, similar to that in other vasculitides.

Disclosure of Interest: None declared


**AB0704**

CLINICAL-ANALYTICAL CHARACTERISATION OF 52 DIAGNOSED PATIENTS OF BEHÇET DISEASE WITH INCLUSION OF PAEDIATRIC CASES IN A SPANISH TERTIARY HOSPITAL

S. Zegarra Mondragon, A. Alia-Jimenez, C. Bouroncle Alaluna, A. Boteanu. Rheumatology, Hospital Ramon y Cajal (Spain), Madrid, Spain

Background: Behçet’s disease (BD) is a chronic and recurrent inflammatory disease of unknown etiology, classified into polygenetic autoinflammatory diseases or variable vessel vasculitis. It has a wide spectrum of symptoms with a very variable range of severity, from mucocutaneous involvement to neurological manifestations, systemic vasculitis or severe ocular manifestations. About 5.4%–7.6% of Behçet’s cases have a paediatric debut.

Objectives: To evaluate and compare the clinical and laboratory manifestations of a series of 52 patients, adults and children, diagnosed with BD according to the classification criteria of the International Study Group of BD (ISGBD-1990).

Methods: Retrospective cross-sectional observational study, which included 43 adult patients and 9 paediatric patients diagnosed with BD in the Rheumatology Department of a Madrid tertiary hospital. The clinical-analytical characteristics of both groups were evaluated, as well as the correlation of HLA-B51 with the described symptomatology.

Results: The mean age at diagnosis of BD was 36.9±11.8 years in adults and 11.4±5.1 years in children. 27.3% of adults and 11.1% of children with BD were male, with oral ulcers close to 90% in both groups. Contrary to what was reported in other series, genital ulcers were more frequent in children (77.8% versus 65.9% of adults), as was the presence of uveitis (44.4% in children compared to 22.7% in adults) and neurological manifestations (22.2% in children versus 6.8% in adults). Joint involvement was also more frequent in children (88.9% versus 52.3% in adults), as well as fever (44% in children versus 14% in adults); being these two manifestations the only parameters that were associated in a statistically significant way with their presentation in the paediatric age in BD. In contrast, skin involvement and vascular manifestations were more frequent in adults. The positivity of HLA-B51 did not correlate statistically with any clinical manifestation, but those who had it had a mean age at diagnosis of 26.5 years compared to a mean of 39 years in those who did not present this genetic marker.

Conclusions: Behçet’s disease presents with a wide spectrum of clinical manifestations, potentially serious, ranging from skin lesions to neurological or vascular manifestations. In our series, patients diagnosed at paediatric age most frequently had systemic manifestations (fever), arthritis or severe clinical manifestations such as neurological involvement or uveitis. Limitations: a small number of paediatric cases included in our study.

Disclosure of Interest: None declared


**AB0705**

LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS ASSOCIATED WITH AORTIC VALVE SURGERY IN PATIENTS WITH TAKAYASU ARTERITIS AND AORTIC VALVEREGERUPTATION

S.H. Nam1, O.C. Kwon1, W.J. Seo2, Y.-G. Kim1, C.-K. Lee1, B. Yoo1, S. Hong1, Internal medicine, Asan Medical Center,Internal medicine, Veterans Health Service Medical Center, Seoul, Korea, Republic of Ireland

Background: Some patients with Takayasu arteritis (TA) have aortic valve (AV) involvement, which can lead to aortic regurgitation (AR). However, data on the long-term outcomes, including survival of TA patients with AR, are lacking. Moreover, previous studies were limited to patients who underwent AV surgery.

Objectives: This study aimed to characterise the long-term outcomes and clinical characteristics of TA patients with AR regardless of whether they underwent surgical or non-surgical intervention.

Methods: Medical records of patients with TA between January 1995 and December 2015 were retrospectively reviewed. AR was diagnosed using transthoracic echocardiography. Poor outcomes were defined as all-cause death and major adverse cardiac and cerebrovascular events (MACCE). Multivariate analysis was performed to determine the factors affecting poor prognosis in the surgical group.

Results: Of the total 105 patients with TA and AR, 41 (39.0%) underwent AV surgery. Among patients who underwent AV surgery, inflammation values (Erythrocyte sedimentation rate, 62.0±7.311 mm/hr vs. 39.16±28.4 mm/hr; C-reactive protein, 3.66±4.1 mg/dL vs. 0.92±1.7 mg/dL; AR degree (3.56±0.7 grade vs. 2.08±1.0 grade), and sinus diameter (32.74±5.7 mm vs. 33.22±4.5 mm) were significantly higher than in those who did not undergo AV surgery. Long-term survival and freedom from MACCE were not significantly different between the groups (10 year survival, 84.3% vs. 79.4%; p=0.827; 10 year event-free survival, 51.8% vs. 71.2%; p=0.29). Twelve of the 41 patients who underwent AV surgery had a poor outcome during follow-up (median, 92.5 months; IQR, 54.5–183.5), and eight of them had a recurrence of AR requiring reoperation. Multivariate Cox analysis revealed that coronary disease [hazard ratio (HR), 4.234; 95% confidence interval (CI), 1.381–12.979; p=0.012], LV dysfunction (HR, 3.387; 95% CI, 1.143–10.042; p=0.028), and impaired renal function (HR, 19.983; 95% CI, 3.480–114.731; p<0.001) were significant risk factors associated with poor outcomes at follow-up (table 1).


<table>
<thead>
<tr>
<th>Variables</th>
<th>HR</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary disease*</td>
<td>4.234</td>
<td>1.381–12.979</td>
<td>0.012</td>
</tr>
<tr>
<td>LV dysfunction**</td>
<td>3.387</td>
<td>1.143–10.042</td>
<td>0.028</td>
</tr>
<tr>
<td>Impaired renal function</td>
<td>19.983</td>
<td>3.480–114.731</td>
<td>0.001</td>
</tr>
</tbody>
</table>

*coronary disease: severity is more than moderate stenosis
**LV dysfunction: EF <50%

Conclusions: In patients with TA with AV involvement, there were no significant differences between long-term survival rate and event-free survival (MACCE) among those who had or had not undergone AV surgery. In the surgical group, the prognosis was poor when coronary artery disease, LV dysfunction, and renal impairment were present at the time of surgery.

Disclosure of Interest: None declared


**AB0706**

Ocular presentation in granulomatosis with polyangiitis (gpa) patients: relation to autoantibodies and disease activity

T.A. Gheita1, E.M. Abd El-Latif2, 1Rheumatology and Clinical Immunology, Faculty of Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo; 2Ophthalmology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Objectives: To study the disease characteristics, autoantibodies and activity in granulomatosis with polyangiitis (GPA) patients with ocular manifestations.

Methods: 46 GPA patients visiting the ophthalmology clinic were included. Ocular manifestations, clinical and slit lamp examination were performed. The Birmingham Vasculitis Activity Score (BVAS) was recorded. Laboratory investigations were recorded and the antineutrophil cytoplasmic antibody (ANCA) performed.

Results: The median age of the patients was 44.5 (32–63) years, 22 males:24 females and disease duration 6.5 (1–16) years. Ocular manifestations were present in all patients; 12 (26.1%) had proteinosia, 40 (87%) scleritis/episcleritis with perforation in 3 (6.5%), keratoconjunctivitis in 33 (71.7%) – acute infiltrative stromal keratitis in 11, peripheral ulcerative keratitis in 15 and sclerosing keratitis in 11 patients. Uveitis was present in 11 (23.9%) and retinal changes included vasculitis, exudates and haemorrhage was present in 7 (15.2%). 43 (93.5%) of the patients had blurring of vision and vision loss was present in 2 (4.3%). Glaucoma was present in 4 (8.7%). Impairment was bilateral in 32 (69.6%) patients. Rheumatoid factor was positive in 56.5% and significantly associated with uveitis (p<0.04) while ANA was positive in 45.7% and significantly associated with keratoconjunctivitis (p<0.04). BVAS tended to be higher in those with uveitis (p<0.05).

Conclusions: Ocular involvement must be considered in all GPA patients and referral to an experienced ophthalmologist is mandatory for proper management and improved outcome of such a rare systemic disease. ANA and RF positivity may raise suspicion for KC or uveitis respectively. There was a remarkable association between uveitis and disease activity.

Disclosure of Interest: None declared


Downloaded from http://ard.bmj.com/ on November 5, 2023 by guest. Protected by copyright.